Krogerus advises Stifel on Faron's rights offering

Krogerus advised Stifel Europe Securities SAS as the sole global coordinator and sole bookrunner on Faron Pharmaceuticals' rights offering of approximately EUR 40.1 million.

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies and its shares are listed on Nasdaq First North Growth Market Finland and as depositary interests on AIM in the United Kingdom.

The offering was fully committed at launch, comprising subscription commitments, cornerstone commitments and subscription guarantees. The cross-border offering consisted of a rights offering on Nasdaq First North Growth Market Finland and AIM, the market operated by London Stock Exchange plc.

The Krogerus team was led by Partner Tom Fagernäs, and he was assisted by Counsel Anna Sahrakorpi and Joel Kanervo, Senior Associate Peter Partanen, and Associate Helmi Räsänen.